GlassScriptPhysician profile
Jiong-Ming Hu
NPI 1932261716
$14,691.58
in general payments reported to CMS, 2019-2025
37 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $1,428 · 2021: $2,450 · 2022: $2,312 · 2023: $2,069 · 2024: $2,139 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,285 · Education: $51.55 · Consulting Fee: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,285.09 |
| Education | $51.55 |
| Consulting Fee | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,649.12 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $1,641.34 | 2019-2025 | Verquvo, Capvaxive, Lagevrio |
| Amgen INC. | $1,561.46 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,125.69 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $955.64 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novartis Pharmaceuticals Corporation | $917.65 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $796.08 | 2022-2025 | |
| Amarin Pharma, INC. | $734.21 | 2019-2022 | |
| Pfizer INC. | $699.26 | 2019-2025 | |
| Novo Nordisk INC | $638.81 | 2019-2021 | |
| Lilly USA, LLC | $588.47 | 2019-2024 | Mounjaro |
| Esperion Therapeutics, INC. | $571.71 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $532.04 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $431.56 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $403.02 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiong-Ming Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.